Estradiol Patent Expiration

Estradiol was first introduced by Novartis Pharmaceuticals Corp in its drug Estraderm on Sep 10, 1986. Other drugs containing Estradiol are Vagifem, Vivelle, Estrogel, Estring, Menostar, Fempatch, Imvexxy, Estradiol, Climara, Elestrin, Evamist, Alora, Esclim, Divigel, Minivelle, Vivelle-Dot. 39 different companies have introduced drugs containing Estradiol.


Estradiol Patents

Given below is the list of patents protecting Estradiol, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Imvexxy US11266661 Vaginal inserted estradiol pharmaceutical compositions and methods Feb 02, 2034 Mayne Pharma
Imvexxy US10258630 Vaginal inserted estradiol pharmaceutical compositions and methods Nov 21, 2032 Mayne Pharma
Imvexxy US10398708 Vaginal inserted estradiol pharmaceutical compositions and methods Nov 21, 2032 Mayne Pharma
Imvexxy US10471072 Vaginal inserted estradiol pharmaceutical compositions and methods Nov 21, 2032 Mayne Pharma
Imvexxy US10537581 Vaginal inserted estradiol pharmaceutical compositions and methods Nov 21, 2032 Mayne Pharma
Imvexxy US10568891 Vaginal inserted estradiol pharmaceutical compositions and methods Nov 21, 2032 Mayne Pharma
Imvexxy US10668082 Vaginal inserted estradiol pharmaceutical compositions and methods Nov 21, 2032 Mayne Pharma
Imvexxy US10806697 Vaginal inserted estradiol pharmaceutical compositions and methods Nov 21, 2032 Mayne Pharma
Imvexxy US10835487 Vaginal inserted estradiol pharmaceutical compositions and methods Nov 21, 2032 Mayne Pharma
Imvexxy US10888516 Soluble estradiol capsule for vaginal insertion Nov 21, 2032 Mayne Pharma
Imvexxy US11065197 Soluble estradiol capsule for vaginal insertion Nov 21, 2032 Mayne Pharma
Imvexxy US11116717 Soluble estradiol capsule for vaginal insertion Nov 21, 2032 Mayne Pharma
Imvexxy US11123283 Soluble estradiol capsule for vaginal insertion Nov 21, 2032 Mayne Pharma
Imvexxy US11241445 Vaginal inserted estradiol pharmaceutical compositions and methods Nov 21, 2032 Mayne Pharma
Imvexxy US11246875 Vaginal inserted estradiol pharmaceutical compositions and methods Nov 21, 2032 Mayne Pharma
Imvexxy US11304959 Vaginal inserted estradiol pharmaceutical compositions and methods Nov 21, 2032 Mayne Pharma
Imvexxy US11351182 Vaginal inserted estradiol pharmaceutical compositions and methods Nov 21, 2032 Mayne Pharma
Imvexxy US11497709 Vaginal inserted estradiol pharmaceutical compositions and methods Nov 21, 2032 Mayne Pharma
Imvexxy US9180091 Soluble estradiol capsule for vaginal insertion Nov 21, 2032 Mayne Pharma
Imvexxy US9289382 Vaginal inserted estradiol pharmaceutical compositions and methods Nov 21, 2032 Mayne Pharma
Minivelle US8231906 Transdermal estrogen device and delivery Jul 04, 2030 Noven
Minivelle US9724310 Transdermal estrogen device and delivery Jul 10, 2028 Noven
Minivelle US9730900 Transdermal estrogen device and delivery Jul 10, 2028 Noven
Minivelle US9833419 Transdermal estrogen device and delivery Jul 10, 2028 Noven
Vagifem US7018992 Hormone composition Sep 17, 2022

(Expired)

Novo Nordisk Inc
Elestrin US7198801 Formulations for transdermal or transmucosal application Jun 25, 2022

(Expired)

Viatris
Evamist US6978945 Dispensing device Nov 30, 2021

(Expired)

Padagis Us
Elestrin US7470433 Formulations for transdermal or transmucosal application Aug 03, 2021

(Expired)

Viatris
Minivelle US6841716 Patch Apr 27, 2020

(Expired)

Noven
Menostar US5891868 Methods for treating postmenopausal women using ultra-low doses of estrogen Nov 21, 2017

(Expired)

Bayer Hlthcare
Menostar US6692763 Methods for treating postmenopausal women using ultra-low doses of estrogen Nov 21, 2017

(Expired)

Bayer Hlthcare
Vagifem US5860946 Instrument for inserting a suppository Jul 01, 2017

(Expired)

Novo Nordisk Inc
Evamist US6299900 Dermal penetration enhancers and drug delivery systems involving same Feb 19, 2017

(Expired)

Padagis Us
Evamist US6818226 Dermal penetration enhancers and drug delivery systems involving same Feb 19, 2017

(Expired)

Padagis Us
Evamist US6923983 Transdermal delivery of hormones Feb 19, 2017

(Expired)

Padagis Us
Minivelle US5646286 Palladium catalyzed vinylic substitution reactions with 2-substituted-pyridines Aug 12, 2014

(Expired)

Noven
Minivelle US5656286 Solubility parameter based drug delivery system and method for altering drug saturation concentration Aug 12, 2014

(Expired)

Noven
Vivelle-dot US5656286 Solubility parameter based drug delivery system and method for altering drug saturation concentration Aug 12, 2014

(Expired)

Sandoz
Minivelle US6024976 Solubility parameter based drug delivery system and method for altering drug saturation concentration Jan 07, 2014

(Expired)

Noven
Vivelle-dot US6024976 Solubility parameter based drug delivery system and method for altering drug saturation concentration Jan 07, 2014

(Expired)

Sandoz
Vivelle-dot US5474783 Solubility parameter based drug delivery system and method for altering drug saturation concentration Dec 12, 2012

(Expired)

Sandoz
Vivelle-dot US5958446 Solubility parameter based drug delivery system and method for altering drug saturation concentration Dec 12, 2012

(Expired)

Sandoz



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Estradiol's patents.

Given below is the list recent legal activities going on the following patents of Estradiol.

Activity Date Patent Number
Patent litigations
Patent Issue Date Used in PTA Calculation 28 Mar, 2006 US7018992
Recordation of Patent Grant Mailed 28 Mar, 2006 US7018992
Issue Notification Mailed 08 Mar, 2006 US7018992
Receipt into Pubs 23 Feb, 2006 US7018992
Dispatch to FDC 22 Feb, 2006 US7018992
Application Is Considered Ready for Issue 22 Feb, 2006 US7018992
Receipt into Pubs 20 Jan, 2006 US7018992
Printer Rush- No mailing 27 Sep, 2005 US7018992
Pubs Case Remand to TC 06 Sep, 2005 US7018992
Workflow - File Sent to Contractor 03 Jun, 2005 US7018992


Estradiol's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Estradiol Generic API Manufacturers

Several generic applications have been filed for Estradiol. The first generic version for Estradiol was by Bristol Myers Squibb Co Pharmaceutical Research Institute and was approved on Approved Prior to Jan 1, 1982. And the latest generic version is by Encube Ethicals Private Ltd and was approved on Mar 5, 2025.

Given below is the list of companies who have filed for Estradiol generic, along with the locations of their manufacturing plants worldwide.